K030370 · Tetracore, Inc. · NPO · Dec 9, 2003 · Microbiology
Device Facts
Record ID
K030370
Device Name
REDLINE ANTHRAX ALERT TEST
Applicant
Tetracore, Inc.
Product Code
NPO · Microbiology
Decision Date
Dec 9, 2003
Decision
SESE
Submission Type
Traditional
Regulation
21 CFR 866.3045
Device Class
Class 2
Attributes
Real-World Evidence
Real-World Evidence
Submission
Device
Sponsor
RWD Sources
RWE Use Summary
Key Tags
K030370 · Dec 9, 2003
REDLINE ANTHRAX ALERT TEST
Tetracore, Inc.
Field evaluation of clinical/public health laboratory surveillance isolates
A field evaluation was conducted at a laboratory performing B. anthracis surveillance of a contaminated worksite to compare the device performance against gamma phage susceptibility testing on 633 non-hemolytic isolates.
Field evaluation; Surveillance; Clinical isolates
Clinical Evidence
Study Design
Population
Comparator
Key Endpoints
Field evaluation of Alert™; Field evaluation / Method comparison
633 non-hemolytic isolates from a contaminated worksite; Sample Size: 633; Number of Sites: 1
Gamma phage susceptibility testing
Agreement between Alert™ and gamma phage susceptibility
Indications for Use
The Tetracore RedLine Anthrax Alert™ Test is intended for the rapid, in vitro qualitative detection of Bacillus anthracis from non-hemolytic colonies obtained from sheep blood agar plates. The test is intended for use in clinical, public health, and hospital laboratories in conjunction with other markers and testing for the identification of Bacillus anthracis.
Device Story
RedLine Anthrax Alert™ Test is an immunochromatographic assay for presumptive identification of Bacillus anthracis. Input: non-hemolytic colonies from sheep blood agar plates suspended in Colony Isolation Buffer. Operation: reagent strip utilizes monoclonal and polyclonal antibodies to detect B. anthracis antigen in aqueous specimens. Output: qualitative visual result on test cassette. Used in clinical, public health, and hospital laboratories by trained personnel. Results used in conjunction with other markers to support identification of B. anthracis. Benefits: rapid presumptive identification to assist laboratory workflows.
Clinical Evidence
No clinical trials performed. Evidence consists of analytical performance and a field evaluation. Inclusivity testing included 145 B. anthracis strains (98.6% positive). Exclusivity testing included 49 non-hemolytic Bacillus/Bacillus-like species, 52 hemolytic Bacillus species, and 26 non-Bacillus pathogens. Field evaluation of 633 non-hemolytic isolates compared the device to gamma phage susceptibility testing, showing 100% agreement (410 B. anthracis, 223 non-B. anthracis).
Technological Characteristics
Immunochromatographic test cassette; utilizes monoclonal and polyclonal antibodies for antigen detection. Includes Colony Isolation Buffer and Positive Control reagent. Stable for 12 months at 15-30°C.
Indications for Use
Indicated for rapid, in vitro qualitative presumptive identification of Bacillus anthracis from non-hemolytic colonies cultured on sheep blood agar plates. For use in clinical, public health, and hospital laboratories. Not for use with spore preparations, suspicious powders, or samples other than colonies from culture growth.
Regulatory Classification
Identification
An in vitro diagnostic device for Bacillus species (spp.) detection is a prescription device used to detect and differentiate among Bacillus spp. and presumptively identify B. anthracis and other Bacillus spp. from cultured isolates or clinical specimens as an aid in the diagnosis of anthrax and other diseases caused by Bacillus spp. This device may consist of Bacillus spp. antisera conjugated with a fluorescent dye (immunofluorescent reagents) used to presumptively identify bacillus-like organisms in clinical specimens; bacteriophage used for differentiating B. anthracis from other Bacillus spp. based on susceptibility to lysis by the phage; or antigens used to identify antibodies to B. anthracis (anti-toxin and anti-capsular) in serum. Bacillus infections include anthrax (cutaneous, inhalational, or gastrointestinal) caused by B. anthracis, and gastrointestinal disease and non-gastrointestinal infections caused by B. cereus.
Special Controls
*Classification.* Class II (special controls). The special controls are set forth in FDA's special controls guideline document entitled “In Vitro Diagnostic Devices for*Bacillus* spp. Detection; Class II Special Controls Guideline for Industry and Food and Drug Administration Staff.” For availability of the guideline document, see § 866.1(e).(c)
*Restriction on Distribution.* The distribution of these devices is limited to laboratories that follow public health guidelines that address appropriate biosafety conditions, interpretation of test results, and coordination of findings with public health authorities.(d)
*Restriction on Use.* The use of this device is restricted to prescription use and must comply with the following:(1) The device must be in the possession of:
(i)(A) A person, or his agents or employees, regularly and lawfully engaged in the manufacture, transportation, storage, or wholesale or retail distribution of such device; or
(B) A practitioner, such as a physician, licensed by law to use or order the use of such device; and
(ii) The device must be sold only to or on the prescription or other order of such practitioner for use in the course of his professional practice.
(2) The label of the device shall bear the statement “Caution: Federal law restricts this device to sale by or on the order of a ____”, the blank to be filled with the word “physician” or with the descriptive designation of any other practitioner licensed by the law of the State in which he practices to use or order the use of the device.
(3) Any labeling, as defined in section 201(m) of the Federal Food, Drug, and Cosmetic Act, whether or not it is on or within a package from which the device is to be dispensed, distributed by, or on behalf of the manufacturer, packer, or distributor of the device, that furnishes or purports to furnish information for use of the device contains adequate information for such use, including indications, effects, routes, methods, and frequency and duration of administration and any relevant hazards, contraindications, side effects, and precautions, under which practitioners licensed by law to employ the device can use the device safely and for the purposes for which it is intended, including all purposes for which it is advertised or represented. This information will not be required on so-called reminder-piece labeling which calls attention to the name of the device but does not include indications or other use information.
(4) All labeling, except labels and cartons, bearing information for use of the device also bears the date of the issuance or the date of the latest revision of such labeling.
Predicate Devices
preamendments
Submission Summary (Full Text)
{0}
K030370
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE ONLY TEMPLATE
A. 510(k) Number: k030370
B. Analyte: *Bacillus anthracis* cell surface protein
C. Type of Product: Assay kit, Immunochromatographic, Bacillus Anthracis Differential Antibody
D. Applicant: Tetracore, Inc.
E. Proprietary and Established Names of the Product: Redline Alert™ Test
F. Regulatory Information:
1. Regulation section: Unclassified
2. Classification: Unclassified
3. Product code: NPO
4. Panel: 83
G. Intended Use:
Intended use(s): The Tetracore RedLine Alert™ Test is intended for the rapid, *in vitro* qualitative presumptive identification of *Bacillus anthracis* from non-hemolytic *Bacillus* colonies cultured on sheep blood agar plates. The test is intended for use in clinical, public health, and hospital laboratories in conjunction with other markers and testing for the presumptive identification of *Bacillus anthracis*.
Warning: The RedLine Alert™ Test has not been evaluated for use with spore preparations, suspicious powders, or samples other than colonies from culture growth.
1. Indication(s) for use: non-hemolytic Bacillus colonies cultured on sheep blood agar plates
2. Special conditions for use statement(s): used in conjunction with other markers and testing for the presumptive identification of B. anthracis
3. Special instrument requirements: none
H. Device Description:
RedLine Alert™ Test is an immunochromatographic lateral flow cassette-type device. It has a nitrocellulose membrane (backed with a vinyl adhesive support) that is striped with a polyclonal rabbit IgG (*B. anthracis* Sterne vegetative and spore mix used as immunogen) for the T line and a 2nd polyclonal antibody for the C (control) line. The T-line polyclonal is obtained from rabbits immunized with *B. anthracis* Sterne, purified by Protein-G chromatography. The membrane is encased in a plastic cassette-type casing.
Page 1, SE Decision Summary
{1}
K030370
A mouse monoclonal antibody reagent is purified by Protein A chromatography, sterile filtered, preserved in 0.1% NaAzide and conjugated to colloidal gold, and then added to a glass fiber pad that is assembled in the cassette under the cellulose sample pad. An additional cellulose pad is affixed in the cassette assembly at the distal end of the membrane strip to facilitate migration. To use the device, colony isolation buffer is also needed. The kit contains tubes with 7.5 mL of TRIS, EDTA, KCl, Triton-X100 and NaAzide formulated buffer (pH 8.0). Aliquots of 200 μL are used for performing a test.
I. Substantial Equivalence Information (if known):
1. Predicate device name(s): preamendments
2. Predicate 510(k) number(s): preamendments
3. Comparison with predicate:
| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Intended use | Identification and differentiation of B. anthracis from other non-hemolytic Bacillus-like species | Identification and differentiation of B. anthracis from other Bacillus-like species |
| Indications | Adjunct to microbiological culture procedures | Same |
| Differences | | |
| Item | Device | Predicate |
| Antibody type | Monoclonal | Polyclonal |
| Conjugate tag | Colloidal gold | FITC |
| Format | Lateral flow single unit | Fluorescent microscopy |
J. Standard/Guidance Document Referenced (if applicable): NA
K. Test Principle: Alert™ is an immunochromatographic test format with manual preparation of test suspension and visual interpretation of endpoint (presence/absence of a colored line in the T and C stripe regions. A visible colored line appears in the cassette window if antigen (a cell surface protein) homologous with the monoclonal conjugate (murine MAB-colloidal gold) is present in the colony tested. This cell surface protein is also found in some B. cereus and B. thuringiensis strains. However, those strains are invariably hemolytic when cultured on sheep blood agar.
L. Performance Characteristics (provide the information described below as appropriate to support the substantial equivalence determination):
1. Analytical performance:
{2}
K030370
a. Precision/Reproducibility): During inclusivity, exclusivity, and other analytical testing, test replicates of the same organism were done. These were done from different preparations of the same culture and were read by 2 different observers. Intensity of colored lines was also documented by using a densitometric reader (a reflected light optical reader) giving sample values (SV), a semiquantitative scoring. Three of 52 colonies tested were scored as either indeterminate or a faint band by one or more observers.
b. Linearity/Assay reportable range: Variations in cultural growth conditions were assessed. These included 8-48 h incubation times, temperature incubation at both 30° and 37° C, ambient air and CO₂ incubation, and density of test inoculum. Conclusions from these studies: 12-24 h cultures, incubated either ambient or CO₂, and with incubation temperature as low as 30°C provide reliable results.
c. Traceability (controls, calibrators, or method): A positive control material is included in the kit: individual polypropylene tubes of lyophilized supernatant from liquid broth cultures of B. anthracis Sterne. Each cassette contains an internal procedural control, antibody (anti-murine) striped onto the test membrane that captures excess and unbound conjugate. The monoclonal reactive with the cell surface protein is proprietary and there is no standard reference material available.
d. Detection limit: NA – the assay is intended for use with colonies, using a prescribed amount of inoculum. Inclusivity studies were performed with 145 different B. anthracis strains (organisms from 28 different countries on 6 continents and from 12 different states within the US), representing each of the 5 VNTR (variable-number tandem repeats) groups and 53 of the 89 described genotypes. One strain had unusually small atypical colonies. The Alert™ showed positive results for 143/145 (98.6%).
e. Analytical specificity: Exclusivity studies were done with 49 nonhemolytic Bacillus and Bacillus-like spp., 52 hemolytic Bacillus and Bacillus-like spp. and 26 non-Bacillus common pathogens. All non-hemolytic colony types were negative when tested with Alert™; 12 of 52 hemolytic Bacillus spp. were positive with Alert™.
f. Assay cut-off: NA
2. Comparison studies:
a. Method comparison with predicate device: There is no predicate device to use for comparison testing. There are established methods for identification of B. anthracis and for differentiating Bacillus spp. by evaluating different phenotypic characteristics of culture growth, and microscopic and colony morphology. A field evaluation of the Alert™ was done in a laboratory performing testing for B. anthracis surveillance of a contaminated worksite. At this laboratory, 633 nonhemolytic isolates were tested with gamma phage and Alert™. Of these, 410 were identified as B. anthracis and 223 as non-B. anthracis isolates. Results for Alert™ and gamma phage susceptibility agreed for all of these culture isolates. [Note: all B. anthracis in this
Page 3, SE Decision Summary
{3}
K030370
evaluation were Ames strain so sensitivity across a spectrum of different strains cannot be inferred].
b. Matrix description and comparison: NA – the Alert™ is only indicated for use with colonies recovered on sheep blood agar culture plates.
3. Clinical Studies:
a. Clinical sensitivity: NA
b. Clinical specificity: NA
b. Other clinical supportive data (when a and b are not applicable): NA
4. Clinical cut-off (where applicable): NA
5. Expected values/Reference range: NA
M. Conclusion: Substantially equivalent
Page 4, SE Decision Summary
Predicate graph will load when search results are available.
Embedding visualization will load when search results are available.
PDF viewer will load when search results are available.
Loading panels...
Select an item from Submissions
Click any panel, subpart, regulation, product code, or device to see details here.
Section Matches
Results will appear here.
Product Code Matches
Results will appear here.
Special Control Matches
Results will appear here.
Loading collections...
Loading
My Alerts
You will receive email notifications based on the filters and frequency you set for each alert.
Sort by:
Create Alert
Search Filters
Agent Token
Create a read-only bearer token for Claude, ChatGPT, or other agents that can call HTTP APIs.
Copy this now. It will not be shown again.
Connected apps
Apps you authorized through browser sign-in. Disconnecting revokes their access immediately.
Learn the FDA Browser
Two short videos show you everything — or skip straight to the written tutorial if you'd rather read. You can reopen this any time from the Tutorial button in the top bar.
Part 1 — Search, results, and everyday workflows 16 min
Part 2 — Embeddings: the galaxy map 3 min
1. Search: exact and fuzzy
Type a phrase like "coronary artery calcification" into the search box. You get two kinds of results. Exact results match the literal phrase — prefix searches work ("coronary artery calcificati") but suffix searches do not. Fuzzy results match on the meaning and intent of your phrase rather than the exact words, and are sorted by relevance score. Hover over the Exact or Fuzzy badge on any row to see exactly why it matched.
Use the checkboxes above the results to narrow: SaMD keeps only software-only devices, AI / ML keeps only devices with AI.
Exact vs. fuzzy search: what's the difference?
Exact matches on the literal phrase (prefix search works, suffix does not). Fuzzy matches on the meaning and intent of the phrase rather than the exact words. Hover over the badge on any row to see why it matched.
You search "coronary artery calcification" and want only software devices with AI. What two filters do you apply?
Narrow by SaMD (software-only devices), then narrow by AI/ML (devices with AI).
2. The results table
Scroll right in the results table. The intended use is extracted for you — no need to open the PDF. The device story gives a high-level snapshot of what the device does and how it's used. The AI Performance sub-table shows each output name, acceptance criteria, observed values, and development/test dataset descriptions — the same format Innolitics uses for regulatory strategy outputs, and the fastest high-level fingerprint of an AI device. It is AI-generated but has been very reliable in practice.
Where do you find a device's intended use without opening the PDF?
Scroll right in the search results table. The intended use column is extracted for you; no need to dig into the 510(k) summary PDF.
What does the AI Performance sub-table show, and why is it useful?
Output name, acceptance criteria, observed values, development dataset description, and test dataset description. It's the same format we use for regulatory strategy output and Fast 510(k) input, and the fastest high-level fingerprint of an AI device. AI-generated but reliable in practice.
3. Judging fuzzy relevance
Fuzzy results trail off in relevance as you scroll. Use three signals to decide how far down to go: the fuzzy badge explanations, the intended use column, and whether your target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, you're past the relevant zone. A top hit with a low score (~0.4) and a stretched explanation is a hint the closest predicates are far away — the project may be headed for De Novo. Note the fuzzy search is a pattern match: it doesn't handle negation ("not") well, and hardware devices can appear — filter by SaMD/AI ML to cut them.
How do you judge how far down fuzzy search results to go?
Use the relevancy signals: the fuzzy badge explanations, the intended use column, and whether the target output (e.g., Cobb angle) still appears in the AI Performance sub-table. Once it stops appearing, results are trailing off in relevancy.
4. Device detail page: chat and citations
Click a device name to open its detail page: device facts on the left, a chat window on the right. Ask something like "Describe the training data". The answer carries little citation bubbles — click one to jump to the highlighted passage in the source PDF, so you can verify every AI answer against the document. There's also a Download PDF button for sharing.
How do you verify an AI chat answer on the device detail page?
Click the citation bubbles to jump to the relevant highlight in the source document.
Reading rule for every project: how many summaries do you read in full?
At least the three most relevant 510(k) or De Novo summaries, in full. After that, use targeted chat questions to confirm your memory quickly. The tool supports this professional habit — it doesn't replace it.
5. Side-by-side comparison
Select multiple rows in the results table (aim for under ~10), then open the PDF Viewer tab. Ask one question — it goes to all selected devices in parallel, each with citations. This is the fastest way to compare and contrast devices: training data, PCCP scope, how they handled adding new scanners, and so on.
What does the side-by-side PDF viewer mode do?
Select multiple devices, open the PDF viewer tab, and ask one question (e.g., "Describe the training data"). It queries all selected devices simultaneously with citations, so you can compare and contrast quickly.
6. Collections
With rows selected, go to the Collections tab and create a labeled collection (e.g., "Cobb Angle Project"). Reload that selection any time — before a client call, pull up the collection and ask questions across all of its devices at once.
How do you save a set of selected devices for later use?
Select the rows, go to the Collections tab, and create a labeled collection (e.g., "Cobb Angle Project"). You can reload the selection anytime and carry it into the PDF viewer and other tabs that support selections.
7. Product codes and the regulations tree
Click a product code in the results to jump to it in the regulations tree — identification text, sibling product codes, and devices you can open in a PDF viewer on the right. Click a regulation number to see its identification, special controls, and related product codes. You can also search by product code or regulation number at the top of the tree. Always read the special controls if any exist for your device — it broadens your search and sharpens pre-kickoff research.
What can you do from the regulations tree view?
Browse product codes and regulation numbers, read the identification text and special controls, browse sibling product codes, open device PDFs on the right, and search by product code or regulation number at the top of the tree.
8. Chart view
Click Show Chart and segment by regulation number (or product code) to see which regulations dominate your result set. Clicking a regulation takes you into the regulations tree. Great for spotting that most matches are, say, hardware laparoscopic devices — a cue to go back and filter.
How do you see which regulations dominate a search result set?
Click "Show Chart" and segment by Regulation Number. Clicking a regulation takes you to the regulations tree.
9. The predicate graph
Open the Predicates tab for a family-tree view of predicate relationships. Click a node to trace its parents and children; selections from search carry over pre-selected. Commonly predicated devices are worth reading — a lot of people predicated them for a reason. The visual lineage is also handy on client calls, e.g. to show how a predicate family evolved and justify why your predicate still holds.
In the predicate graph, why are commonly predicated devices worth reading?
A lot of people predicated them for a reason. Clicking a node traces parents and children, and selections from search carry over pre-selected.
10. Embeddings: the galaxy map
The Embeddings tab plots every matching document in a 2-D "galaxy map" where semantically similar devices cluster together. Hover or click clusters to explore, and let AI label the clusters for you. Embeddings beat product codes for grouping: two devices can carry different product codes (LLZ vs. QIH) yet do the same thing — the embedding captures the meaning of the intended use and device story. This is also exactly how retrieval-augmented generation (RAG) works under the hood, and it makes a great visual on client calls.
Try it yourself
Head to the search page and work through a few of these AI/ML fuzzy searches to build intuition: perivascular fat on CT · aortic valve calcification opportunistic screening on noncontrast CT · breast cancer prediction on digital pathology slides · autism detection · gestational age prediction · a hearing aid that can also detect a pulse · foundation model based analysis of ECG · large language models · penetration test. Watch how the relevance scores, intended use, and AI Performance tables tell you when results stop being meaningful.
